How much does Gilteritinib cost in the domestic market?

Gilteritinib is a targeted drug used to treat patients with acute myeloid leukemia (AML), especially those carrying FLT3 mutations. Although giritinib is already on the market in China, it is not currently included in the medical insurance system, which means that patients may face higher treatment costs. In addition, domestic channels for purchasing the drug are relatively limited, and many patients may need to obtain it through overseas channels. The price of drugs varies in different markets, especially when there is a significant price difference between original drugs and generic drugs.

In the domestic market, the original drug of gilitinib is mainly divided into two types: European version and Hong Kong version, which are relatively expensive. According to market information, the price of the Hong Kong version of gilitinib is as high as about 100,000 yuan. Such a price is undoubtedly a heavy financial burden for most patients, especially when there is no medical insurance reimbursement. Due to the high price of original drugs, many patients choose to seek other more economical but still effective treatment options.

In contrast, generic versions of giritinib offer a more affordable option. The price of the Lao version of giritinib is approximately between one thousand and two thousand yuan, which is significantly lower than the price of the original drug. This allows patients in need of treatment to obtain drugs at a lower cost, reducing the financial burden. Although the price of generic drugs is lower, their drug ingredients are basically the same as the original drugs, and they can provide patients with the same effective treatment effect.

In general, the price difference of giritinib in the domestic market is mainly reflected between the original drug and generic drugs. Although original drugs are more expensive, generic drugs provide a more viable option for patients with limited financial resources. Patients should comprehensively consider price, efficacy, and purchase channels when making choices to ensure that they receive the treatment plan that best suits their financial situation. If generic drugs are being considered, patients are advised to make the choice under the guidance of a physician to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.xospata.com/